Inotrem is an advanced clinical stage biotechnology company specialized in immunotherapy. The company has developed a new concept of immunomodulation that targets TREM-1, to control unbalanced and dysregulated inflammatory responses.
Inotrem targets the TREM-1 pathway as a key factor in unbalanced inflammatory responses. The company focuses on the therapeutic and diagnostic tools derived from its knowledge of the biology of the TREM-1 pathway.
Inotrem has 2 late-stage clinical programs ongoing in acute inflammatory diseases such as septic shock and COVID-19 with its lead product nangibotide. Inotrem also targets chronic inflammatory diseases through a broad anti-TREM monoclonal antibody program.
Inotrem targets the TREM-1 pathway as a key factor in unbalanced inflammatory responses. The company focuses on the therapeutic and diagnostic tools derived from its knowledge of the biology of the TREM-1 pathway
Inotrem has 2 late-stage clinical programs ongoing in acute inflammatory diseases such as septic shock and COVID-19 with its lead product nangibotide. Inotrem also targets chronic inflammatory diseases through a broad anti-TREM monoclonal antibody program.
We are thrilled and honored to have been chosen for the 3rd year in a row to join the French Tech 120, a government-backed support program dedicated to the most successful and fast-growing start-ups of
We are thrilled and honored to have been chosen for the 3rd year in a row to join the French Tech 120, a government-backed support program dedicated to the most successful and fast-growing start-ups of
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS
Inotrem 2022 – Legal notices
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS
Inotrem 2022- Legal notices